CN1147490C - 呋喃并四吡啶衍生物及其药物组合物和用于治疗神经变形疾病的用途 - Google Patents

呋喃并四吡啶衍生物及其药物组合物和用于治疗神经变形疾病的用途

Info

Publication number
CN1147490C
CN1147490C CNB008027080A CN00802708A CN1147490C CN 1147490 C CN1147490 C CN 1147490C CN B008027080 A CNB008027080 A CN B008027080A CN 00802708 A CN00802708 A CN 00802708A CN 1147490 C CN1147490 C CN 1147490C
Authority
CN
China
Prior art keywords
disease
alkyl
butyl
compound
tetrahydropyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008027080A
Other languages
English (en)
Chinese (zh)
Other versions
CN1336929A (zh
Inventor
D
D·彼德斯
M·戈隆伯格
A·莫勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of CN1336929A publication Critical patent/CN1336929A/zh
Application granted granted Critical
Publication of CN1147490C publication Critical patent/CN1147490C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB008027080A 1999-01-19 2000-01-13 呋喃并四吡啶衍生物及其药物组合物和用于治疗神经变形疾病的用途 Expired - Fee Related CN1147490C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900061 1999-01-19
DKPA199900061 1999-01-19

Publications (2)

Publication Number Publication Date
CN1336929A CN1336929A (zh) 2002-02-20
CN1147490C true CN1147490C (zh) 2004-04-28

Family

ID=8089290

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008027080A Expired - Fee Related CN1147490C (zh) 1999-01-19 2000-01-13 呋喃并四吡啶衍生物及其药物组合物和用于治疗神经变形疾病的用途

Country Status (10)

Country Link
US (1) US6576641B2 (enExample)
EP (1) EP1147113B1 (enExample)
JP (1) JP2002535334A (enExample)
CN (1) CN1147490C (enExample)
AT (1) ATE328887T1 (enExample)
AU (1) AU776276B2 (enExample)
CA (1) CA2353903A1 (enExample)
DE (1) DE60028538T2 (enExample)
NZ (1) NZ512289A (enExample)
WO (1) WO2000043397A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311386T1 (de) * 2001-09-24 2005-12-15 Bayer Pharmaceuticals Corp Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
KR102074089B1 (ko) 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
JP7187437B2 (ja) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク 化合物および組成物ならびにそれらの使用
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN112135827B (zh) 2018-02-16 2024-01-12 赛诺维信制药公司 盐、晶型及其制备方法
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2395028A2 (fr) * 1977-06-22 1979-01-19 Centre Etd Ind Pharma Derives pyridiniques, leur preparation et leurs application therapeutique
FR2566775B1 (fr) 1984-06-27 1986-10-31 Synthelabo Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique
FR2570701B1 (fr) * 1984-09-27 1987-05-22 Synthelabo Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique
FR2635977B1 (fr) * 1988-09-07 1992-05-15 Synthelabo Utilisation de derives de tetrahydro-4,5,6,7 furopyridines pour obtenir des medicaments destines au traitement de l'obesite
GB8921465D0 (en) * 1989-09-22 1989-11-08 Fujisawa Pharmaceutical Co Bicyclic amine compound and a process for the preparation thereof
FR2652579B1 (fr) * 1989-10-02 1992-01-24 Sanofi Sa Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CA2200469A1 (en) * 1994-10-11 1996-04-18 Takeda Chemical Industries, Ltd. Condensed compounds, their production and use
CN1250528C (zh) * 1995-09-11 2006-04-12 阿温蒂斯药物公司 环状硝酮和含有它们的药用组合物

Also Published As

Publication number Publication date
JP2002535334A (ja) 2002-10-22
WO2000043397A1 (en) 2000-07-27
EP1147113A1 (en) 2001-10-24
DE60028538D1 (de) 2006-07-20
ATE328887T1 (de) 2006-06-15
CN1336929A (zh) 2002-02-20
US20020013336A1 (en) 2002-01-31
EP1147113B1 (en) 2006-06-07
AU776276B2 (en) 2004-09-02
NZ512289A (en) 2003-06-30
AU3033300A (en) 2000-08-07
US6576641B2 (en) 2003-06-10
DE60028538T2 (de) 2007-06-21
CA2353903A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
CN111491920B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN113557235A (zh) 用于药物治疗的杂环化合物
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
CN110256440B (zh) 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途
CN107501110A (zh) 富马酸酯前体药物及其在治疗多种疾病中的应用
CN1703404A (zh) 制备10,11－二氢－10－羟基－5H－二苯并(b,f)氮杂䓬－5－甲酰胺的两种对映异构体的对映选择性方法及其新晶形
CN1368960A (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1147490C (zh) 呋喃并四吡啶衍生物及其药物组合物和用于治疗神经变形疾病的用途
EP3828174A1 (en) Pyridazinone derivative
JP6898310B2 (ja) ６員アザヘテロ環を含有するデルタ−オピオイド受容体調節化合物、同化合物を使用する方法、および同化合物を作る方法
AU2014211728B2 (en) Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
CN111565718A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US11220503B2 (en) Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof
CN111788182A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
JP2023500263A (ja) アドレナリン受容体ａｄｒａｃ２の阻害剤
CN1326456A (zh) 8－氮杂二环[3,.2.1]辛－2－烯及－辛烷衍生物
JP2022036285A (ja) ピペリジニルノシセプチン受容体化合物
AU2018221148B2 (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
JP4588444B2 (ja) ジアザビシクロノナン及び−デカン誘導体並びにこれをオピオイドレセプターリガンドとして使用する方法
US20210261513A1 (en) 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors
JP2014073982A (ja) 新規ベンズイミダゾール誘導体からなる医薬
MX2007001042A (es) Nuevos derivados de benzoilurea.
CN1318067A (zh) 用于刺激神经元生长和延伸的化合物、组合物和方法
EP2185525B1 (fr) Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
HK40077526B (zh) 对核受体具有活性的化合物

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040428

Termination date: 20120113